KEI letter to USTR Katherine Tai regarding WTO negotiations on therapeutics and diagnostics for COVID 19
Author: James Love
KEI review of 62 COVID 19 contracts reveals 59 authorizations for non-voluntary use of third party patents under 28 USC 1498
Since the COVID 19 Pandemic began, there has been a spirited debate over patent rights, including a highly publicized 20 month debate over a proposed WTO waiver on intellectual property rights. During that time a handful of countries have taken… Continue Reading
KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)
KEI comments to WHO INB on the Open Source Dividend
The June 17, 2022 WTO Ministerial Decision on the TRIPS Agreement
Updated Friday, 17 June 2022, 11:30 AM Geneva time. Early Friday morning, 17 June 2022, the WTO’s 12th Ministerial Conference (chaired by Timur Suleymenov, Kazakshstan), adopted a Ministerial Decision on the TRIPS Agreement (WT/MIN(22)/W/15/Rev.2). The text can be found here.… Continue Reading
KEI questions on WIPO Broadcast treaty (SCCR 42)
28 questions for broadcast treaty May 12, 2022 Term of protection 1. The 1971 Convention for the Protection of Producers of Phonograms Against Unauthorized Duplication of Their Phonograms and The 1974 Brussels Convention Relating to the Distribution of Programme-Carrying Signals… Continue Reading
KEI Comments on the proposed WIPO broadcast treaty, May 10, 2022
These were my notes from the KEI intervention on Tuesday, May 10, 2022, at WIPO SCCR 42, on the proposed WIPO broadcasting treaty. This is essentially a related rights treaty, and goes far beyond the control of signal piracy. And… Continue Reading
Pfizer’s March 18, 2022 opposition to the KEI request for a compulsory license in Dominican Republic for Paxlovid.
On March 18, 2022, Pfizer filed a 45 page opposition to the KEI application for a compulsory license on Paxlovid patents in the Dominican Republican. This is the Pfizer filing, and KEI’s unofficial translation. Pfizer-opposition-DR-CL-18March2022.pdf Translation-Pfizer-opposition-KEI-CL-Paxlovid-18march2022.pdf The December 3, 2021… Continue Reading
QUAD’s tentative agreement on TRIPS and COVID 19
See also the following essays in Medium: The proposed WTO agreement on intellectual property and COVID 19 vaccines should not require that authorizations of non-voluntary use of patents list all patents covered, Medium, March 17, 2022. The Quad WTO proposal… Continue Reading
KEI comments to USTR and the Trade Policy Staff Committee (TPSC) on Trade related aspects of public goods
https://www.regulations.gov/comment/USTR-2021-0021-0120 Trade related aspects of public goods Submission to USTR and the Trade Policy Staff Committee (TPSC) James Love, KEI March 8, 2022 Introduction One can think of the economy as including both public and private goods, each valued by… Continue Reading